The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors

Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study

(2019) Alice Bitossi et al.   MEDIATORS OF INFLAMMATION

Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis

(2018) Claudia Fabiani et al.   CLINICAL RHEUMATOLOGY

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis

(2018) Andrew D. Dick et al.   OPHTHALMOLOGY

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France

(2018) Jérôme Avouac et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Biosimilar switching and related medical liability

(2018) Paolo Rocco et al.   Journal of Forensic and Legal Medicine

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease

(2018) Giuseppe Lopalco et al.   Internal and Emergency Medicine

Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab

(2018) Nayoung Lee et al.   mAbs

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

(2017) Claudia Fabiani et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study

(2016) Claudia Fabiani et al.   CLINICAL RHEUMATOLOGY

Uveitic macular edema

(2016) C Fardeau et al.   EYE

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)

(2016) Juyong Hong et al.   mAbs

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept

(2016) Ick Hyun Cho et al.   mAbs

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

(2016) Andrew D. Dick et al.   OPHTHALMOLOGY

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders

(2013) Grace Levy-Clarke et al.   OPHTHALMOLOGY